NEW YORK, February 3, 2020 \u2013 OrbiMed is pleased to announce the promotion of David Bonita, M.D., to General Partner. David joins the firm\u2019s six existing General Partners, Sven H. Borho, Carl Gordon, Jonathan Silverstein, Carter Neild, Geoffrey Hsu and Scot Stevens. <\/p>\n\n\n\n
Since joining OrbiMed in 2004, David has led numerous transformative investments in innovative biopharmaceutical and medical device companies, including Loxo Oncology, Tricida, Cryterion Medical, and Therachon SAS, among others.<\/p>\n\n\n\n
\u201cDavid\u2019s investments have contributed significantly to the financial returns enjoyed by OrbiMed\u2019s clients, but more importantly his companies have discovered and developed numerous therapies that treat life threatening unmet medical needs.\u201d stated Jonathan Silverstein, a Managing Partner of OrbiMed.<\/p>\n\n\n\n
\u201cDavid\u2019s promotion to General Partner is a recognition of his extraordinary contributions to the firm in recent decades,\u201d stated Managing Partner Carl Gordon. \u201cWe look forward to his growing organizational leadership in the years to come.\u201d<\/p>\n\n\n\n
David can be reached at (212) 739-6400 or BonitaD@OrbiMed.com<\/p>\n\n\n\n